Sutro Biopharma has appointed Dr Jeremy Bender as chief business officer and Dr Aaron Sato as VP, research, as it prepares to advance development of its cancer antibodies.
Dr Bender joins from Allos Therapeutics, where he was VP, corporate development, responsible for mergers and acquisitions, financing transactions, product in-and out-licensing and strategic planning.
During his time at Allos, he set up a collaboration with Mundipharma for the co-development and commercialisation of lymphoma therapy Folotyn (pralatrexate) outside the US and Canada.
He was also heavily involved in the acquisition of Allos by Spectrum Pharmaceuticals.
Dr Sato joins Sutro from OncoMed Pharmaceuticals, where he served as senior director of antibody engineering.
Prior to this, Dr Sato held director positions at Dyax, where he oversaw multiple external collaborations with major pharmaceutical companies.
“Dr Bender’s broad skill set in corporate business development and strategic collaborations will help us maximise the select business opportunities we are actively pursuing,” said William Newell, CEO of Sutro.
“Dr Sato’s expertise in antibody and protein engineering and phage display driven discovery is important to Sutro’s design and development of next-generation antibody drug conjugates and bifunctional antibody-based therapeutics.”